A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (BEAT-MS)
The purpose of this study is to compare efficacy and safety of Autologous Hematopoietic Stem Cell Transplant (AHSCT) to best available therapy (BAT) in relapsing MS. Best available therapy is referring to the best available medications that are used to treat MS. Patients who agree to participate in the experimental treatment study will be randomly chosen (like a coin flip) to have an AHSCT or BAT. Neither you nor your doctor are able to decide which treatment you will receive. In addition, patients interested in participating must have permission from their insurance company to enter the trial.
- Study Identifier: 842819
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required